Zoetis Inc. (ZTS): Cost of Revenue
$2.67B
Year ended 2025-12-31
+2.8%
3-year compound annual growth
+5.3%
5-year compound annual growth
+4.4%
10-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.67B | -1.9% | 2026-02-12, From 2025-01-01 |
| 2024-12-31 | $2.72B | +6.2% | 2026-02-12, From 2024-01-01 |
| 2023-12-31 | $2.56B | +4.4% | 2026-02-12, From 2023-01-01 |
| 2022-12-31 | $2.45B | +6.6% | 2025-02-13, From 2022-01-01 |
| 2021-12-31 | $2.30B | +12.0% | 2024-02-13, From 2021-01-01 |
| 2020-12-31 | $2.06B | +3.3% | 2023-02-14, From 2020-01-01 |
| 2019-12-31 | $1.99B | +4.2% | 2022-02-15, From 2019-01-01 |
| 2018-12-31 | $1.91B | +7.7% | 2021-02-16, From 2018-01-01 |
| 2017-12-31 | $1.77B | +6.5% | 2020-02-13, From 2017-01-01 |
| 2016-12-31 | $1.67B | -4.1% | 2019-02-14, From 2016-01-01 |
| 2015-12-31 | $1.74B | +1.2% | 2018-02-15, From 2015-01-01 |
| 2014-12-31 | $1.72B | +2.9% | 2017-02-16, From 2014-01-01 |
| 2013-12-31 | $1.67B | +6.8% | 2016-02-24, From 2013-01-01 |
| 2012-12-31 | $1.56B | -5.4% | 2015-02-27, From 2012-01-01 |
| 2011-12-31 | $1.65B | n/a | 2014-03-26, From 2011-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Zoetis Inc. (ZTS) | 2025-12-31 | $2.67B | -1.9% |
| Vertex Pharmaceuticals Inc (VRTX) | 2025-12-31 | $1.65B | +7.9% |
| Viatris Inc (VTRS) | 2025-12-31 | $9.29B | +1.9% |
| Organon & Co. (OGN) | 2025-12-31 | $2.90B | +8.0% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $8.32B | -1.9% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $2.12B | +5.9% |
| Perrigo Co PLC (PRGO) | 2025-12-31 | $2.76B | -2.5% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $677.17M | +120.9% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $717.44M | +23.6% |
Compare ZTS, VRTX, VTRS, OGN side by side · Screen every company in Pharmaceutical Preparations ↗